SCHEMBL2743668

SCHEMBL2743668

COc1cc2c(c(OC)c1OC)-c1cc3c(cc1COC2)OCO3

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
ATR Q13535 1/20 0.51
ADRA1A P35348 2/20 0.49
DRD1 P21728 2/20 0.49
RAD52 P43351 1/20 0.49
ADRB1 P08588 1/20 0.49
ADRA2A P08913 1/20 0.49
DRD2 P14416 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
DRD4 P21917 1/20 0.49
DRD5 P21918 1/20 0.49
HRH2 P25021 1/20 0.49
ADRA1D P25100 1/20 0.49
HTR1D P28221 1/20 0.49
HTR1B P28222 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7437553 0.83 GSK3B (0.54) GSK3BMEN1KMT2AATRADRA1A
SCHEMBL2744244 0.76 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2744245 0.75 TUBB4A (0.50) DRD1DRD2HTR2ATUBB4ATUBB
Stegane SCHEMBL5014561 0.73 TUBB4A (0.53) GSK3BMEN1KMT2AATRADRA1A
Picrostegane SCHEMBL14097820 0.73 TUBB4A (0.53) GSK3BMEN1KMT2AATRADRA1A
SCHEMBL6429218 0.72 TUBB4A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2743793 0.70 CYP3A4 (0.44) GSK3BMEN1KMT2AATRPOLB
SCHEMBL2743641 0.70 ATM (0.49) POLBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3573727 0.70 TUBB4A (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2743594 0.70 TUBB4A (0.48) GSK3BKMT2AHTR2BTUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178578-B2 Chemical compounds THE UNIVERSITY OF MANCHESTER (GB) 2012-05-15 US claimed
US-20100016261-A1 CHEMICAL COMPOUNDS THE UNIVERSITY OF MANCHESTER (GB) 2010-01-21 US claimed
US-8178578-B2 Chemical compounds THE UNIVERSITY OF MANCHESTER (GB) 2012-05-15 US disclosed
US-8178578-B2 Chemical compounds THE UNIVERSITY OF MANCHESTER (GB) 2012-05-15 US disclosed
US-8178578-B2 Chemical compounds THE UNIVERSITY OF MANCHESTER (GB) 2012-05-15 US disclosed
US-20100016261-A1 CHEMICAL COMPOUNDS THE UNIVERSITY OF MANCHESTER (GB) 2010-01-21 US disclosed
US-20100016261-A1 CHEMICAL COMPOUNDS THE UNIVERSITY OF MANCHESTER (GB) 2010-01-21 US disclosed
US-20100016261-A1 CHEMICAL COMPOUNDS THE UNIVERSITY OF MANCHESTER (GB) 2010-01-21 US disclosed
WO-2008075048-A2 POLYALKYLOXYDIBENZ ( C, E) OXEPINE DERIVATIVES AS MEDICAMENTS THE UNIVERSITY OF MANCHESTER (GB) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016261-A1 CHEMICAL COMPOUNDS CYP11B2, MPO, PIGO GSK3B 2541/4885MEN1 907/4885KMT2A 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.